



ORIGINAL ARTICLE

## Worsening or 'pseudo-worsening' renal function? The prognostic value of hemoconcentration in patients admitted with acute heart failure



José Luís Martins\*, Luís Santos, Ana Faustino, Jesus Viana, José Santos

Department of Cardiology, Baixo Vouga Hospital Centre, Aveiro, Portugal

Received 25 May 2017; accepted 8 October 2017

### KEYWORDS

Cardiorenal  
syndrome;  
Worsening renal  
function;  
Hemoconcentration

### Abstract

**Introduction:** Renal insufficiency, as evidenced by an increase in creatinine, is associated with higher mortality in patients with acute heart failure (AHF). Conversely, hemoconcentration (HC) in AHF is associated with lower mortality, but can also cause an increase in creatinine. Our aim was to assess the prognosis of HC in patients hospitalized for AHF presenting with or without worsening renal function (WRF).

**Methods:** A total of 618 consecutive patients admitted for AHF were included. WRF was defined according to the Kidney Disease Improving Global Outcomes (KDIGO) criteria and HC was defined as an elevation of hemoglobin during hospitalization compared to the admission value. Six-month all-cause mortality was analyzed.

**Results:** The patients' mean age was  $79 \pm 11$  years; 58% were women. Mortality at six months was 38% and 49% of patients had WRF. HC occurred in 38.9% of patients with WRF and was associated with improved survival (HR 1.6, 95% CI 1.10-2.34;  $p=0.02$ ) compared to WRF without HC. HC was associated with better survival in KDIGO stages 1 and 2 (HR 1.8; 95% CI 1.1-2.8;  $p=0.01$ ). For patients without chronic kidney disease (CKD) with WRF in stages 1 and 2, HC was associated with significantly better survival (HR 2.3; 95% CI 1.2-4.2;  $p=0.01$ ).

**Conclusion:** In patients admitted for AHF without renal failure or CKD, WRF with HC is associated with a better prognosis, similar to that of patients without WRF, and should therefore be reclassified as 'pseudo-WRF'.

© 2018 Sociedade Portuguesa de Cardiologia. Published by Elsevier España, S.L.U. All rights reserved.

\* Corresponding author.

E-mail address: [zeluismartins@gmail.com](mailto:zeluismartins@gmail.com) (J.L. Martins).

**PALAVRAS-CHAVE**

Síndrome  
cardiorrenal;  
Agravamento  
da função renal;  
Hemoconcentração

## Agravamento da função renal ou «pseudo-agravamento da função renal?». O impacto prognóstico da hemoconcentração em doentes admitidos com insuficiência cardíaca aguda

**Resumo**

**Introdução:** Alterações na função renal com aumento da creatinina têm sido associadas a maior mortalidade em doentes com insuficiência cardíaca aguda (ICA). Já a hemoconcentração na ICA tem-se associado a redução da mortalidade, é também uma causa de elevação da creatinina. Avaliar o prognóstico da hemoconcentração (HC) em doentes hospitalizados por ICA com e sem agravamento da função renal (AFR).

**Métodos:** Analisados 618 doentes consecutivos admitidos por ICA. Definido agravamento da função renal de acordo com os critérios KDIGO e HC como elevação da hemoglobina durante a hospitalização comparativamente à admissão. Avaliada morte por qualquer causa aos seis meses.

**Resultados:** A idade média foi  $79 \pm 11$  anos; 58% mulheres. A mortalidade aos seis meses foi de 38%; 49% dos doentes tiveram AFR. HC ocorreu em 38,9% dos doentes com AFR e associou-se a maior sobrevivência após ajuste de fatores demográficos e comorbilidades (HR 1,6; IC95%: 1,06–2,33;  $p=0,026$ ), comparativamente a AFR sem HC. Na avaliação por estádios KDIGO, HC associou-se a maior sobrevivência nos estádios 1 e 2 (HR 1,8; IC95%: 1,1–2,8;  $p=0,01$ ). Nos doentes com doença renal crónica (DRC) com AFR nos estádios 1 e 2, a HC esteve associada a maior sobrevivência (HR 2,3, IC95%: 1,2–4,2,  $p=0,01$ ).

**Conclusão:** Em doentes admitidos por ICA sem falência renal ou DRC, o AFR com HC está associada a bom prognóstico. O seu prognóstico é similar a doentes sem AFR e deverá assim ser reclassificado como «pseudo-AFR».

© 2018 Sociedade Portuguesa de Cardiologia. Publicado por Elsevier España, S.L.U. Todos os direitos reservados.

**Introduction**

Heart failure is a chronic systemic disease, the symptoms and natural history of which are related to neurohormonal dysregulation impacting water and sodium retention.<sup>1</sup> Kidney disease is one of the most important comorbidities and its presence is a powerful predictor of poor outcomes in patients with heart failure.<sup>1</sup> Only 9% of the 118 465 patients admitted with acute heart failure (AHF) in the Acute Decompensated Heart Failure National Registry (ADHERE) had normal renal function (defined as glomerular filtration rate [GFR]  $\geq 90$  ml/min/1.73 m<sup>2</sup>).<sup>2</sup>

Worsening renal function (WRF) occurs in 30–50% of patients admitted with heart failure, depending on the definition used. It is associated with higher rehospitalization rates, increased length of hospital stay, higher mortality (with one-year mortality around 30%), and greater health costs.<sup>3–5</sup>

Historically, impairment of renal function has been attributed to low cardiac output and resulting renal hypoperfusion.<sup>6,7</sup> Nevertheless, there is growing evidence that other factors, such as tubular structural damage, systemic venous congestion and elevated intra-abdominal pressure, are strongly associated with WRF.<sup>6–13</sup>

It has been suggested that AHF patients with mild creatinine elevation but without established renal failure have a better prognosis, since these changes are due to hemoconcentration (HC) rather than to true WRF.<sup>14–18</sup>

Our aim was to assess HC in patients hospitalized for AHF presenting with or without WRF and to determine its prognostic value.

**Methods****Study design**

This was a single-center retrospective study of patients admitted for AHF. Clinical, laboratory, and echocardiographic data were collected.

The protocol was approved by the head of our institution's cardiology department and the ethics committee in March 2014, in accordance with the principles of the Helsinki Declaration and national regulations.

**Patients and eligibility criteria**

We enrolled 618 consecutive patients admitted to our cardiology department for AHF between January 1 and December 31, 2012.

AHF was defined as the rapid onset of symptoms and signs secondary to abnormal cardiac function and the presence of objective evidence of a structural or functional abnormality of the heart at rest (cardiomegaly, third heart sound, cardiac murmur, echocardiographic abnormality or elevated natriuretic peptides). These diagnostic criteria were in accordance with the 2016 European Society of Cardiology heart failure guidelines.<sup>7</sup>

**Table 1** Kidney Disease Improving Global Outcomes classification of acute kidney injury.

Stage	Serum creatinine
1	1.5-1.9 times baseline or $\geq 0.3$ mg/dl ( $\geq 265$ $\mu$ mol/l) increase
2	2.0-2.9 times baseline
3	3.0 times baseline or increase in serum creatinine to $\geq 4$ mg/dl ( $\geq 353.6$ $\mu$ mol/l) or initiation of renal replacement therapy or in patients <18 years, decrease in eGFR to <35 ml/min/1.73 m <sup>2</sup>

eGFR: estimated glomerular filtration rate.

Patients were excluded if they met the following criteria: absence of creatinine measurement during the first two days of hospitalization, hospital stay  $\leq 48$  hours, or end-stage renal disease on dialysis.

### Initial data collection

An extensive review of clinical records from outpatient clinics, hospital wards and emergency department admissions was performed by two co-investigators. The following data were collected: demographics, previous medical history (including smoking, diabetes, hypertension, coronary heart disease, chronic kidney disease [CKD] and previous AHF), physical examination (signs and symptoms of AHF, blood pressure, heart rate), etiology and triggers of AHF, laboratory values (including baseline serum urea and creatinine levels; hemoglobin and hematocrit at admission; admission and discharge levels of urea, creatinine, sodium and potassium), medications administered during hospitalization for AHF (including furosemide doses), length of hospital stay, and date of death.

Baseline creatinine was defined as a value measured within three months of admission. When this value was not available, it was calculated by the Modification of Diet in Renal Disease (MDRD) equation according to the recommendations of the Acute Dialysis Quality Initiative Working Group.<sup>19</sup>

Baseline estimated GFR (eGFR) was calculated based on the MDRD study equation, using the baseline creatinine value.

Change in renal function was calculated as the absolute difference between creatinine at admission and repeat value measured 48-72 hours following admission. WRF was defined as an increase in creatinine of  $\geq 0.3$  mg/dl and was classified according to the Kidney Disease Improving Global Outcomes (KDIGO) criteria (Table 1).<sup>20</sup> For our classification, only serum creatinine was taken in account, since urine output values were difficult to collect.

HC was defined as an increase in hemoglobin during hospital stay. When there was WRF at admission (compared to baseline creatinine), hemoglobin variation was calculated by subtracting hemoglobin at discharge from hemoglobin at admission; when there was no WRF at admission, hemoglobin variation was calculated by subtracting hemoglobin on the day of peak creatinine value from hemoglobin at admission.

The furosemide dose was converted to furosemide equivalents, with 40 mg of oral furosemide corresponding to 20 mg of intravenous furosemide. Mean daily loop diuretic doses were calculated by dividing the total dose (in furosemide

equivalents) used during hospital stay by the length of hospital stay (in days).

Left ventricular ejection fraction (LVEF) was assessed by transthoracic echocardiography during the index hospitalization or within six months of admission.

### Statistical analysis

Continuous variables were expressed as mean  $\pm$  standard deviation or median (interquartile range [IQR]), and categorical variables were expressed as number and percentage. Survival curves were plotted and stratified using the Kaplan-Meier method. The log-rank test was used to test for differences between survival curves. A Cox proportional hazards model was used for multivariate analysis. Statistical analyses were performed with IBM SPSS for Windows, version 21.

## Results

### Study population

The baseline characteristics of the 618 patients enrolled in the study are summarized in Table 2. Their mean age was  $79 \pm 11$  years, 358 (58%) were women, 60% had hypertension, 27.7% dyslipidemia, 36.2% diabetes and 20.5% previous ischemic heart disease. The most frequent etiology of heart failure was ischemic heart disease (20.5%), followed by valvular disease (10%) and hypertensive cardiomyopathy (9.7%). The most common trigger of AHF was respiratory infection (40%), followed by myocardial infarction (7.8%) and arrhythmias (7.8%). Overall, 67% of patients were medicated prior to hospital admission with loop diuretics, 65% with angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, 32.4% with beta-blockers, 15.9% with mineralocorticoid receptor antagonists and 12% with digoxin. The median length of hospital stay was seven (IQR: 3-12) days. WRF occurred in 49% of patients; when stratified according to the KDIGO classification, 56% of them were in stage 1, 28% in stage 2 and 17% in stage 3. Notably, patients with WRF during hospital stay were older ( $81 \pm 8.8$  vs.  $78.1 \pm 12$  years,  $p < 0.001$ ) and had longer hospital stay (eight vs. seven days;  $p = 0.03$ ), with no difference in the mean dose of diuretic used (59 vs. 60 furosemide equivalents;  $p = 0.6$ ). HC occurred in 38.9% of patients with WRF and in 47.3% of patients without WRF. During six-month follow-up, 38% (n=235) of patients died.

**Table 2** Baseline demographic and clinical characteristics of the study population stratified by serum creatinine levels at admission.


	Total	WRF (n=303)	No WRF (n=315)	p
<i>Age, years</i>	79±11	81±8.8	78.1±12	<0.001
<i>Female</i>	58.1%	60.1%	56.2%	0.33
<i>Risk factors</i>				
Hypertension	60.7%	61.1%	60.3%	0.85
Dyslipidemia	27.7%	24.8%	30.5%	0.11
Diabetes	36.2%	39.6%	34.3%	0.17
CAD	20.5%	20.5%	20.6%	0.97
Smoking	4.5%	2.6%	6.3%	0.03
COPD	21.2%	21.1%	21.3%	0.96
CKD	22.5%	30.7%	14.6%	<0.01
Stroke	9.5%	8.9%	10.2%	0.60
Dementia	5.8%	4.6%	7%	0.21
Cirrhosis	1.5%	1%	1.9%	0.34
Malignancy	11.5%	12.5%	10.5%	0.42
<i>Vital signs</i>				
Heart rate	91±25	91±26	90±25	0.96
SBP	135±32	133±32	137±31	0.09
DBP	72±19	71±20	74±19	0.05
<i>Echocardiography</i>				
LVEF	43±14	42±15	44±13	0.36
<i>Biomarkers</i>				
Troponin I	0 (0.08)	0.01 (0.09)	0 (0.06)	0.08
Pro-BNP	4171 (8805)	6714 (10971)	2795 (5992)	<0.001
Admission serum sodium	137 (6)	137 (5.4)	136 (6)	0.27
Admission potassium	4.5 (0.9)	4.6 (0.9)	4.4 (0.9)	0.03
Discharge serum sodium	138 (6)	138 (6.4)	137 (5.6)	0.14
Discharge potassium	4.2 (0.8)	4.2 (0.9)	4.1 (0.7)	0.01
ASP	30 (24)	31 (27)	30 (23)	0.43
ALT	41 (27)	40 (30)	41 (25)	0.94
ALP	113 (65)	120 (74)	111 (53)	0.06
TC	161 (59)	151 (61)	165 (59)	0.10
CRP	2.6 (6.6)	2.8 (6.8)	2.3 (6.4)	0.11
Baseline urea	45.7 (44)	47.5 (47.8)	43.2 (40.6)	0.73
Baseline creatinine	1.01 (0.5)	1 (0.5)	1.02 (0.44)	0.17
Admission urea	67 (55)	88 (71)	55 (34.5)	<0.001
Admission creatinine	1.4 (0.9)	1.7 (1.1)	1.1 (0.6)	<0.001
Admission hemoglobin	12.2 (3)	11.9 (2.8)	12.5 (2.9)	0.003
Hematocrit	38 (9)	37 (8.5)	38.9 (9.1)	0.003
HC	43.2%	38.9%	47.3%	0.036
Length of hospital stay	7 (9)	8 (9)	7 (8)	0.03
Furosemide equivalent (mg/day)	60 (41)	59 (40)	60 (42)	0.56
WRF day	1 (3)	1 (3)	0	
<i>KDIGO classification</i>				
Stage 1		56%		
Stage 2		28%		
Stage 3		17%		
<i>Prior treatment</i>				
ACEIs/ARBs	65%	67%	63.2%	0.32
Beta-blockers	32.4%	34%	30.8%	0.40
CCBs	25.2%	28.1%	22.5%	0.12
Loop diuretics	66.7%	70.6%	62.9%	0.04
Thiazide diuretics	12.1%	14.5%	9.8%	0.08
MRAs	15.9%	18.2%	13.7%	0.13
Digoxin	11.7%	7.9%	15.2%	<0.01
Nitrates	15.5%	17.2%	14%	0.27
Statins	37.2%	38.6%	35.9%	0.48
Antiarrhythmics	17.5%	20.8%	14.3%	0.03
Antiplatelet therapy	43%	45.2%	41%	0.29
Oral anticoagulants	13.9%	13.2%	14.6%	0.62

Table 2 (Continued)

	Total	WRF (n=303)	No WRF (n=315)	p
Oral antidiabetics	20.6%	20.5%	20.6%	0.96
<b>Etiology</b>				
Coronary disease	19.4%	19.5%	19.4%	0.98
Cor pulmonale	5%	5%	5.1%	0.94
Dilated cardiomyopathy	4.9%	3.6%	6.1%	0.15
HCM	0.6%	0.7%	0.6%	0.97
Hypertensive cardiomyopathy	9.7%	8.9%	10.5%	0.42
Arrhythmia	4.1%	3.6%	4.5%	0.91
Valvular heart disease	10%	10.9%	9.2%	0.48
Unknown	46.2%	47.9%	44.6%	0.44
<b>Triggering factors</b>				
Respiratory infection	40%	37.4%	42.5%	0.21
Infection (not respiratory)	5.7%	6.6%	4.8%	0.32
Anemia	3.7%	4.3%	3.2%	0.46
MI	7.8%	6%	9.6%	0.10
Therapeutic compliance	4.9%	4.6%	5.1%	0.79
Arrhythmia	7.8%	8.6%	7%	0.46
Valvular disease	2.1%	3%	1.3%	0.14
Hypertensive crisis	3.9%	4.6%	3.2	0.35
Pulmonary embolism	0.5%	1%	0%	0.08
Unknown	23.6%	23.9%	23.3%	0.91

Continuous variables are expressed as mean  $\pm$  standard deviation or median (interquartile range) according to normality unless otherwise specified; categorical variables are presented as percentages.

ACEIs: angiotensin-converting enzyme inhibitors; ALP: alkaline phosphatase; ALT: alanine transaminase; ARBs: angiotensin II receptor blockers; ASP: aspartate transaminase; CAD: coronary artery disease; CCBs: calcium channel blockers; CKD: chronic kidney disease; COPD: chronic obstructive pulmonary disease; CRP: C-reactive protein; DBP: diastolic blood pressure; HC: hemoconcentration; HCM: hypertrophic cardiomyopathy; KDIGO: Kidney Disease Improving Global Outcomes; LVEF: left ventricular ejection fraction; MRAs: mineralocorticoid receptor antagonists; MI: myocardial infarction; Pro-BNP: pro-brain natriuretic peptide; SBP: systolic blood pressure; TC: total cholesterol; WRF: worsening renal function.



**Figure 1** Survival curves grouped by presence or absence of worsening renal function (WRF) during hospitalization. Log rank  $p=0.001$ .

### Prognostic value of worsening renal function

Patients without WRF during hospital stay had better survival than those with WRF (log rank  $p=0.001$ ) (Figure 1).


**Table 3** Prognostic value of hemoconcentration in patients with and without worsening renal function.

	HC vs. no HC (log rank p)
WRF	Log rank 8.492; $p=0.004$
No WRF	Log rank 1.757; $p=0.185$
Total	Log rank 2.148; $p=0.143$


HC: hemoconcentration; WRF: worsening renal function.

### Prognostic value of hemoconcentration


In patients with WRF, HC was associated with improved survival after adjustment for demographics and comorbidities (hazard ratio [HR] 1.6; 95% confidence interval [CI] 1.10-2.34;  $p=0.02$ ) compared to those without HC (Table 3 and Figure 2). In terms of KDIGO staging, HC was associated with increased survival in stages 1 and 2 after adjustment for age, gender, hypertension, systolic blood pressure, diabetes, CKD, admission hemoglobin, admission creatinine and admission serum sodium (HR 1.76; 95% CI 1.12-2.76;  $p=0.01$ ), with no significant difference for patients at stage 3 (log rank  $p=0.7$ ) (Figure 3). Patients with HC and WRF in stages 1 and 2 had similar outcomes to those without WRF, regardless of the presence of HC during hospital stay (log rank  $p=0.01$ ) (Figure 4).



**Figure 2** Survival curves grouped by presence or absence of hemoconcentration in patients with worsening renal function.




**Figure 3** Survival curves grouped by presence or absence of hemoconcentration according to the Kidney Disease Improving Global Outcomes criteria. Log rank  $p=0.004$ . HR 1.6; 95% CI 1.10-2.34;  $p=0.02$ . HC: hemoconcentration; WRF: worsening renal function.



**Figure 4** Survival curves grouped by presence or absence of hemoconcentration in Kidney Disease Improving Global Outcomes stage 1 and 2 worsening renal function. HR 1.76; 95% CI 1.12-2.76;  $p=0.01$ .

### Prognostic value of hemoconcentration for mortality according to baseline renal function

For patients without CKD with WRF in stages 1 and 2, HC was associated with significantly better survival both before



**Figure 5** Survival curves grouped by presence or absence of hemoconcentration (HC) according to KDIGO criteria among patients without chronic kidney disease with worsening renal function (WRF). Log rank;  $p=0.02$ .

(HR 2.8; 95% CI 1.5-5.1;  $p=0.001$ ) and after adjustment for baseline characteristics (HR 2.3; 95% CI 1.2-4.2;  $p=0.01$ ) (Figure 5) which, interestingly, did not differ significantly among CKD patients (log rank  $p=0.4$ ) (Table 4).

## Discussion

Our findings show that among patients hospitalized for AHF with WRF and without renal failure (stage 3) or CKD, HC is associated with a better prognosis, similar to patients without WRF. Thus, HC is a protective response to anticongestive therapy and an increase in creatinine in this setting is not associated with a worse prognosis, as opposed to the poorer prognosis that corresponds to an increase in creatinine due to acute kidney injury.

This study extends and corroborates the results obtained in previous studies by confirming a positive association between HC and WRF.<sup>15,21</sup>

The pathophysiological mechanisms responsible for cardiorenal syndrome are complex and multifactorial, and are not fully understood.<sup>22,23</sup>

Intuitively, hemodynamic dysregulation is the pathophysiological basis. Decreased cardiac output and fluid redistribution lead to decreased renal perfusion and to compensatory stimulation of the sympathetic nervous system and renin-angiotensin-aldosterone system. In the long term, these changes induce adverse effects on the heart and kidney by promoting fibrosis, apoptosis and ventricular remodeling.<sup>22,24</sup>

However, there is evidence that renal hypoperfusion is not the major pathophysiological basis for cardiorenal syndrome, as the proportion of patients with hypotension at admission is relatively small in large registries.<sup>2,25</sup> This is corroborated by Mullens et al., who reported that patients who developed WRF did not have a lower cardiac index at admission than those without WRF.<sup>9</sup>

Isolated temporary elevation of central venous pressure (CVP) is associated with decreased renal perfusion and GFR. Winton, for example, observed that diuresis by an

**Table 4** Prognostic value of hemoconcentration for mortality according to baseline renal function.

	With CKD (log rank p)	Without CKD (log rank p)
No WRF and HC	Log rank p=0.14	Log rank p=0.71
WRF stage 1 and 2 and HC	Log rank p=0.43	Log rank p<0.0001; HR 2.26; 95% CI 1.20-4.24; p=0.01
WRF stage 3 and HC	Log rank p=0.35	Log rank p=0.34

CI: confidence interval; CKD: chronic kidney disease; HC: hemoconcentration; HR: hazard ratio; WRF: worsening renal function.

isolated canine kidney was markedly reduced at a renal venous pressure of 20 mmHg and was abolished at pressures >25 mmHg.<sup>26</sup> In addition, an early experiment in normal individuals concluded that producing an intra-abdominal pressure of 20 mmHg with abdominal compression markedly reduced GFR.<sup>27</sup> However, this evidence has not been consistent, with CVP proving to be an independent predictor of WRF, particularly in low cardiac output situations.<sup>28–30</sup>

Elevation of cytokines and other inflammatory markers has been reported in patients with AHF. It has been proposed that inflammatory cytokines such as tumor necrosis factor play a role in sodium retention, myocardial dysfunction, acute renal dysfunction, and vascular injury.<sup>31</sup> Colombo et al. showed that in normal individuals, peripheral venous congestion triggers the release of inflammatory mediators and the activation of endothelial cells.<sup>32</sup>

The response to anticongestive therapy in patients with AHF varies dramatically. In some patients, diuretics can lead to intravascular volume depletion, reduction of renal perfusion and deterioration of renal function. In others, it can decrease venous congestion and therefore improve GFR.<sup>14–16,33,34</sup>

In the Diuretic Optimization Strategies Evaluation (DOSE) trial, transient WRF with the use of high-dose diuretics was associated with early clinical improvement and was not associated with a worse prognosis at 60 days.<sup>34</sup> In 599 consecutive patients with AHF, Metra et al. found that the prognostic value of WRF was mainly determined by the presence of congestion; in the absence of congestion, increases in serum creatinine levels had no prognostic value. By contrast, WRF was strongly associated with a higher risk of adverse outcomes in patients with persistent congestion.<sup>14</sup> Similarly, in an analysis of the ESCAPE trial, Testani et al. showed that HC was associated with both renal impairment and better outcomes.<sup>15</sup>

These studies are in line with our finding that in patients hospitalized for AHF, the clinical impact of changes in creatinine is largely determined by baseline renal function and by response to anticongestive therapy. In our study, in contrast to Breidhardt et al.,<sup>21</sup> HC was prognostic only in WRF patients and had no prognostic value in patients without WRF.

The main conclusion of our study was that HC as a surrogate for anticongestive therapy had prognostic value in patients without CKD but with elevated creatinine. According to our results, it is essential to measure baseline renal function when interpreting renal function in patients with AHF. When creatinine elevation occurs with CKD prior to hospitalization, special care should be taken when treating these patients. Nevertheless, in patients without renal impairment, a slight to moderate increase in creatinine when accompanied by HC may merely represent effective

diuresis, and an increase in serum creatinine accompanied by improvement of heart failure signs and symptoms does not appear to be associated with a poor prognosis.

These results suggest that it may be a mistake to assume that an elevation of creatinine alone means that the patient has acute kidney injury. Acute kidney injury indicates that renal injury has occurred, which may or may not be reversible. However, in our study, WRF associated with HC and without renal failure or CKD correlated with increased survival, similar to patients without WRF, suggesting that this kind of WRF should be reclassified as 'pseudo-WRF'.

Our results highlight the importance of assessing changes in creatinine compared to baseline renal function in patients with AHF.

## Limitations

Our study has several limitations. Our data were collected and analyzed retrospectively, so baseline serum creatinine and LVEF measurements were not available for all patients. Treatments at discharge were not assessed, so the effect of pharmacological treatment on prognosis could not be assessed with this design. We describe the results of a single-center study with a limited number of enrolled patients. A larger sample from other centers would better assess the prognostic value of HC and WRF in AHF patients and would validate our results.

## Conclusion

In patients admitted for AHF without renal failure or CKD, WRF with HC is associated with a better prognosis, similar to the prognosis of patients without WRF. This should therefore be reclassified as 'pseudo-WRF'. Our findings suggest that it is not the increase in creatinine that determines prognosis, but rather the clinical context in which the increase in creatinine occurs. Future studies are required to obtain further insight into the pathophysiological mechanisms of AHF and to seek ways to improve the diagnostic and prognostic accuracy of current methods, as well as to explore effective treatments.

## Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

## Conflicts of interest

The authors have no conflicts of interest to declare.

## References

- Damman K, Valente MA, Voors AA, et al. Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. *Eur Heart J*. 2014;35:455–69.
- Heywood JT, Fonarow GC, Costanzo MR, et al., ADHERE Scientific Advisory Committee and Investigators. High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. *J Card Fail*. 2007;13:422–30.
- Chen J, Normand ST, Wang Y, et al. National and regional trends in heart failure hospitalization and mortality rates for Medicare beneficiaries, 1998–2008. *JAMA*. 2011;306:1669–78.
- Solomon SD, Dobson G, Pocock A, et al. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. *Circulation*. 2007;116:1482–7.
- Tavazzi L, Maggioni AP, Lucci D, et al. Nationwide survey on acute heart failure in cardiology ward services in Italy. *Eur Heart J*. 2006;27:1207–15.
- Ljungman S, Laragh JH, Cody RJ. Role of the kidney in congestive heart failure. Relationship of cardiac index to kidney function. *Drugs*. 1990;39 Suppl. 4:10–21 [discussion 22–24].
- Ponikowski P, Voors AA, Anker SD, et al., ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2016 of the European Society of Cardiology. Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur Heart J*. 2016;37:2129–200.
- Damman K, Ng Kam Chuen MJ, MacFadyen RJ, et al. Volume status and diuretic therapy in systolic heart failure and the detection of early abnormalities in renal and tubular function. *J Am Coll Cardiol*. 2011;57:2233–41.
- Mullens W, Abrahams Z, Francis GS, et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. *J Am Coll Cardiol*. 2009;53:589–96.
- Ross EA. Congestive renal failure: the pathophysiology and treatment of renal venous hypertension. *J Card Fail*. 2012;18:930–8.
- Paterna S, Parrinello G, Cannizzaro S, et al. Medium term effects of different dosage of diuretic, sodium, and fluid administration on neurohormonal and clinical outcome in patients with recently compensated heart failure. *Am J Cardiol*. 2009;103:93–102.
- Mullens W, Abrahams Z, Francis GS, et al. Prompt reduction in intra-abdominal pressure following large-volume mechanical fluid removal improves renal insufficiency in refractory decompensated heart failure. *J Card Fail*. 2008;14:508–14.
- Mullens W, Abrahams Z, Skouri HN, et al. Elevated intra-abdominal pressure in acute decompensated heart failure: a potential contributor to worsening renal function? *J Am Coll Cardiol*. 2008;51:300–6.
- Metra M, Davison B, Bettari L, et al. Is worsening renal function an ominous prognostic sign in patients with acute heart failure? The role of congestion and its interaction with renal function. *Circ Heart Fail*. 2012;5:54–62.
- Testani JM, Chen J, McCauley BD, et al. Potential effects of aggressive decongestion during the treatment of decompensated heart failure on renal function and survival. *Circulation*. 2010;122:265–72.
- Greene SJ, Gheorghide M, Vaduganathan M, et al. Haemoconcentration, renal function, and post-discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. *Eur J Heart Fail*. 2013;15:1401–11.
- van der Meer P, Postmus D, Ponikowski P, et al. The predictive value of short-term changes in hemoglobin concentration in patients presenting with acute decompensated heart failure. *J Am Coll Cardiol*. 2013;61:1973–81.
- Núñez J, García S, Núñez E, et al. Early serum creatinine changes and outcomes in patients admitted for acute heart failure: the cardio-renal syndrome revisited. *Eur Heart J Acute Cardiovasc Care*. 2015, 2048872614540094.
- Bagshaw SM, Cruz DN, Aspromonte N, et al. Epidemiology of cardio-renal syndromes: workgroup statements from the 7th ADQI Consensus Conference. *Nephrol Dial Transplant*. 2010;25:1406–16.
- Roy AK, Mc Gorrian C, Treacy C, et al. A comparison of traditional and novel definitions (RIFLE, AKIN, and KDIGO) of acute kidney injury for the prediction of outcomes in acute decompensated heart failure. *Cardiorenal Med*. 2013;3:26–37.
- Breidhart T, Weidmann ZM, Twerenbold R, et al. Impact of haemoconcentration during acute heart failure therapy on mortality and its relationship with worsening renal function. *Eur J Heart Fail*. 2017;19:226–36.
- Ronco C, McCullough P, Anker SD, et al. Cardio-renal syndromes: report from the consensus conference of the Acute Dialysis Quality Initiative. *Eur Heart J*. 2010;31:703–11.
- Ronco C, Cicoira M, McCullough PA. Cardiorenal syndrome type 1. Pathophysiological crosstalk leading to combined heart and kidney dysfunction in the setting of acutely decompensated heart failure. *J Am Coll Cardiol*. 2012;60:1031–42.
- Damman K, Voors AA, Navis G, et al. The cardiorenal syndrome in heart failure. *Prog Cardiovasc Dis*. 2011;54:14–53.
- Núñez J, Núñez E, Fonarow GC, et al. Differential prognostic effect of systolic blood pressure on mortality according to left-ventricular function in patients with acute heart failure. *Eur J Heart Fail*. 2010;12:38–44.
- Winton FR. The influence of venous pressure on the isolated mammalian kidney. *J Physiol*. 1931;72:49–61.
- Bradley SE, Bradley GP. The effect of increased intra-abdominal pressure on renal function in man. *J Clin Invest*. 1947;26:1010–5.
- Nohria A, Hasselblad V, Stebbins A, et al. Cardiorenal interactions: insights from the ESCAPE trial. *J Am Coll Cardiol*. 2008;51:1268–74.
- Uthoff H, Breidhart T, Klima T, et al. Central venous pressure and impaired renal function in patients with acute heart failure. *Eur J Heart Fail*. 2011;13:432–9.
- Testani JM, McCauley BD, Kimmel SE, et al. Characteristics of patients with improvement or worsening in renal function during treatment of acute decompensated heart failure. *Am J Cardiol*. 2010;106:1763–9.
- Milo O, Cotter G, Kaluski E, et al. Comparison of inflammatory and neurohormonal activation in cardiogenic pulmonary edema secondary to ischemic versus nonischemic causes. *Am J Cardiol*. 2003;92:222–6.
- Colombo PC, Onat D, Harxhi A, et al. Peripheral venous congestion causes inflammation, neurohormonal, and endothelial cell activation. *Eur Heart J*. 2014;35:448–54.
- Givertz MM, Postmus D, Hillege HL, et al. Renal function trajectories and clinical outcomes in acute heart failure. *Circ Heart Fail*. 2014;7:59–67.
- Felker GM, Lee KL, Bull DA, et al. Diuretic strategies in patients with acute decompensated heart failure. *N Engl J Med*. 2011;364:797–805.